Coumarins (including Hydrogenated) Patents (Class 514/457)
  • Patent number: 10278389
    Abstract: This disclosure relates to a method for the control or repellency of biting arthropods. The method comprises bringing the biting arthropods into contact with a biting arthropod repellent formulation. The biting arthropod repellent formulation comprises an alkoxy nootkatol separate from, or in combination, or in synergistic combination, with skin or plant derived compounds and compounds structurally similar to them (e.g., ketones, cyclic ketones, esters, gamma or delta lactones, and branched and/or unsaturated carboxylic acids), and/or one or more repellents selected from the group consisting of DEET®, para-menthane-3,8-diol (PMD), Picaridin, ethyl 3-[acetyl(butyl)amino]propanoate (IR3535), and other nitrogen-containing repellents including amines, amides, and nitrogen-containing heterocyclic compounds.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 7, 2019
    Assignee: Bedoukian Research, Inc.
    Inventors: Robert H. Bedoukian, Patrick Murray Foley
  • Patent number: 9617583
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: April 11, 2017
    Assignee: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Patent number: 9402834
    Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 2, 2016
    Assignee: Ions Pharmaceutical S.à r.l.
    Inventors: Gene H. Zaid, Thomas W. Burgoyne
  • Patent number: 9400273
    Abstract: Described herein are compounds, methods, and kits for long-term tracking of cell proliferation, differentiation, and/or function. The compounds of the present invention are novel cell-tracking reagents, efficiently excitable with a 405-nm violet laser, that provide bright fluorescence intensity, uniform cell staining, and good retention within cells as well as low toxicity toward cells.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 26, 2016
    Assignee: Life Technologies Corporation
    Inventors: Jixiang Liu, Hee Chol Kang, Kyle Gee, Christopher Langsdorf, Jolene Bradford, Gayle Buller
  • Patent number: 9278100
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: March 8, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Lee Honigberg, Erik Verner, Joseph Buggy, David Loury, Wei Chen
  • Patent number: 9238637
    Abstract: The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: January 19, 2016
    Assignee: BEIJING BETTA PHARMACEUTICALS CO., LTD
    Inventors: Xinshan Kang, Wei Long, Fei Wang, Cunbo Ma, Liufeng Zhou, Yunyan Hu, Yanping Wang, Hong Cao, Yinxiang Wang, Fenlai Tan
  • Patent number: 9144245
    Abstract: A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: September 29, 2015
    Assignee: Brandeis University
    Inventors: Daniel Perlman, Kenneth C. Hayes
  • Publication number: 20150141424
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 21, 2015
    Inventors: Qingping ZENG, Andras TORO, John Bruce PATTERSON, Warren Stanfield WADE, Zoltan ZUBOVICS, Yun YANG, Zhipeng WU
  • Publication number: 20150133434
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency vims. The methods generally involve contacting an HIV-infected cell in which HIV is latent with an agent that binds a bromodomain (BRD) in the cell. Latently infected cells contain replication-competent integrated HIV-1 genomes that are blocked at the transcriptional level, resulting in the absence of viral protein expression. The present disclosure provides methods for reducing the reservoir of latent immunodeficiency virus in an individual.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 14, 2015
    Inventors: Melanie Ott, Eric M. Verdin, Ming-Ming Zhou
  • Publication number: 20150133493
    Abstract: Compounds including those of the Formula I where X, R1, R2 and subscript t are as defined herein, useful as ?-secretase inhibitors, are provided, as are compositions comprising the compounds, as well as methods for use of the compounds for treating or preventing neurodegenerative diseases, such as, for instance, Alzheimer's disease.
    Type: Application
    Filed: July 3, 2014
    Publication date: May 14, 2015
    Inventors: Lei Zhu, Hakim Djaballah, Yueming Li, Christopher Chad Shelton
  • Publication number: 20150126473
    Abstract: The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle is useful in diagnostic assays, which are also provided.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 7, 2015
    Applicant: Children's Hospital & Research Center at Oakland
    Inventors: Ronald M. Krauss, Mohmed Elfatih Ashmaig
  • Publication number: 20150111888
    Abstract: The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 23, 2015
    Inventors: Ryoji Yao, Hiroyuki Osada, Yasumitsu Kondoh
  • Publication number: 20150104387
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Application
    Filed: April 2, 2014
    Publication date: April 16, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
  • Patent number: 8969407
    Abstract: At least one compound selected from among coumarin and/or derivative thereof, butylated hydroxyanisole, ethoxyquine and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote hair regrowth, are useful for preventing and/or limiting and/or stopping the development of canities.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 3, 2015
    Assignee: L'Oreal
    Inventor: Stephane Commo
  • Patent number: 8957109
    Abstract: Chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: February 17, 2015
    Assignee: MEI Pharma, Inc.
    Inventors: Andrew Heaton, Alan Husband
  • Publication number: 20150011619
    Abstract: The present disclosure relates to an anti-acne formulation comprising at least one active ingredient selected from the group consisting of coumarin based compounds of Formula I and Formula II; or pharmaceutically acceptable salts, polymorphs and derivatives thereof, and at least one pharmaceutically acceptable excipient. The present disclosure also relates to its application for preventing/curing/treating various acne conditions.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 8, 2015
    Applicant: PIRAMAL ENTERPRISES LIMITED
    Inventors: Somesh Sharma, Ashish Suthar, Kavita Salkar, Sandip Kedar
  • Publication number: 20150011512
    Abstract: The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 8, 2015
    Inventors: Steven Albert Everett, Saraj Ulhaq
  • Patent number: 8906959
    Abstract: A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: December 9, 2014
    Assignee: Brandeis University
    Inventors: Daniel Perlman, Kenneth C. Hayes
  • Patent number: 8901109
    Abstract: This invention relates to a composition containing quercetin, vitamin B3, vitamin C, and folic acid. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: December 2, 2014
    Assignee: Quercegen Pharmaceuticals LLC
    Inventor: Thomas Christian Lines
  • Publication number: 20140343137
    Abstract: The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed.
    Type: Application
    Filed: July 30, 2012
    Publication date: November 20, 2014
    Applicants: BEIJING BETTA PHARMACEUTICALS CO., LTD.
    Inventors: Xinshan Kang, Wei Long, Fei Wang, Cunbo Ma, Liufeng Zhou, Yunyan Hu, Yanping Wang, Hong Cao, Yinxiang Wang, Fenlai Tan
  • Publication number: 20140329897
    Abstract: New pharmaceutical compositions extracted from Ferula assa-foetida are confirmed to effectively treat influenza A (H1N1) virus. The extraction method of the new pharmaceutical compositions mainly includes steps of: (a) extracting F. assa-foetida with methanol to obtain a crude extract; (b) fractioning the crude extract with n-hexane-methanol to obtain a methanol extract; (c) fractioning the methanol extract with chloroform-water to obtain a chloroform extract; and (d) chromatographing the chloroform extract to obtain the pharmaceutical compositions, which can be further fractioned and chromatographed to obtain various sesquiterpene coumarins.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventors: Yang-Chang WU, Fang-Rong CHANG, Lien-Chai CHIANG
  • Publication number: 20140322315
    Abstract: Provided herein are methods and compositions for treating ischemia or a disease or disorder that causes ischemia comprising contacting a subject with cysteamine, a cysteamine derivative, cystamine or a cystamine derivative. The disclosure also provides methods of modulating adiponectin levels in a subject comprising contact a subject with cysteamine, a cysteamine derivative, cystamine or a cystamine derivative.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 30, 2014
    Applicant: The Regents of the University of California
    Inventors: Ranjan Dohil, Susan A. Phillips
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Patent number: 8858991
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Pathologica LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Publication number: 20140303119
    Abstract: The present invention teaches a method and new use for anticoagulant compounds for the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) and other conditions. CRVO and BRVO represent debilitating conditions for which there is currently no effective therapy. The present invention teaches a new therapy, including new uses for existing pharmacological agents, comprising enoxaparin sodium, warfarin, clopidrogel, and others, in the treatment of these and other conditions.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 9, 2014
    Applicant: DiLorenzo Biomedical, LLC
    Inventor: Daniel John DiLorenzo
  • Publication number: 20140301975
    Abstract: Methods of treating blood disorders are described.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventor: Susan P. Perrine
  • Publication number: 20140296270
    Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 2, 2014
    Applicant: Baylor College of Medicine
    Inventors: David J. Tweardy, Xuejun Xu, Moses M. Kasembeli
  • Publication number: 20140296232
    Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicants: Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
  • Publication number: 20140286962
    Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
    Type: Application
    Filed: March 19, 2014
    Publication date: September 25, 2014
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Mayur MOVALIA, Andrea ILLINGWORTH, Susan FAAS MCKNIGHT, Russell P. ROTHER
  • Publication number: 20140249214
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on warfarin therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 4, 2014
    Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Rene Braeckman, William Stirtan, Paresh Soni
  • Publication number: 20140243385
    Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. Also disclosed are novel mercaptan compounds, particularly those including a photolabile protecting group, as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 28, 2014
    Applicant: Encore Health, LLC
    Inventors: William GARNER, Margaret Garner, Ronald D. Blum
  • Publication number: 20140235619
    Abstract: This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.
    Type: Application
    Filed: November 26, 2013
    Publication date: August 21, 2014
    Applicant: NONO INC.
    Inventors: Xiujun Sun, Michael Tymianski, David Garman
  • Patent number: 8809388
    Abstract: A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (PMF) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° C. and fluid at 35° C., and includes between 15% and 45% by weight linoleic acid. The weight ratio of disaturated triglyceride (DST) molecules to trisaturated triglyceride (TST) molecules is greater than 10:1, and the PMF hardstock fat contains approximately 50% to 95% by weight DST molecules, the majority of which contain either palmitic acid or a combination of palmitic and stearic acids at the sn-1 and sn-3 triglyceride positions and either oleic acid or linoleic acid at the sn-2 molecular position.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: August 19, 2014
    Assignee: Brandeis University
    Inventors: Daniel Perlman, Kenneth C. Hayes
  • Patent number: 8802723
    Abstract: A metabolic syndrome relieving agent that is free from a problem of side effects and can be taken for a long term is provided. Aurapten is used as an agent for relieving a metabolic syndrome. Since aurapten has functions of activating PPAR? and PPAR?, promoting the secretion of adiponectin in adipocytes and inhibiting the generation of VLDLs in hepatic cells, it is possible to prevent or treat diseases such as insulin resistance, hyperinsulinism, type 2 diabetes, obesity, visceral fat obesity, hypertension, hyperlipemia, arteriosclerosis and the like and thus prevent or treat the metabolic syndrome. Also, as understood from the fact that citrus fruits such as a hassaku orange, a sweet summer orange or the like containing aurapten have been eaten for many years, they have no problems in terms of safety and have a low calorie content, and therefore, they can be taken for a long term.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: August 12, 2014
    Assignee: ARKRAY, Inc.
    Inventor: Takao Sasaki
  • Publication number: 20140221423
    Abstract: This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.
    Type: Application
    Filed: June 15, 2012
    Publication date: August 7, 2014
    Inventors: Xiujun Sun, Michael Tymianski
  • Patent number: 8778894
    Abstract: The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: July 15, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Deyan Luo, Roland Douglas Shytle
  • Publication number: 20140187625
    Abstract: A novel compound obtained from molecules of the coumarin family, which exhibits rodenticidal activity. Also, compositions which incorporate such compounds and the use thereof for combating rodent pests.
    Type: Application
    Filed: July 19, 2012
    Publication date: July 3, 2014
    Applicant: LIPHATECH
    Inventors: Herve Caruel, Adrien Montagut Romans, Etienne Benoit, Stephane Besse, Philippe Berney, Virginie Lattard
  • Patent number: 8759378
    Abstract: Methods of treating blood disorders are described.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: June 24, 2014
    Assignee: Phoenicia Biosciences, Inc.
    Inventors: Susan P Perrine, Regine Bohacek
  • Publication number: 20140148480
    Abstract: A compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting of hydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a —O—R12 group, wherein R12 is a C1-C7 alkyl, a group —CH2—O—CO—R5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group —O—R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a —CH2— amine, R?1 represents a group chosen among hydrogen and —O—R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for the treatment of pathologies involving excess activity of at least one member of the kallikrein family.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 29, 2014
    Applicant: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Michele REBOUD-RAVAUX, Chahrazade YERROUM-EL AMRI, Xiao TAN, Lixian QIN, Maurice PAGANO, Alain HOVNANIAN, Laetitia FURIO, Bernard PIROTTE
  • Publication number: 20140148400
    Abstract: Derivatized coumarin-based pharmaceutical compositions and methods to use them are provided. The compositions are characterized in that they inhibit the activity of tumor-related CAIX and CAXII to a greater degree than they inhibit the activity of CAI and CAII. The compositions can be used to suppress tumor growth and/or suppress tumor metastases in a mammal.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 29, 2014
    Applicants: METASIGNAL THERAPEUTICS INC., CNRS-DIRE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventors: Claudiu Supuran, Shoukat Dedhar, Fabrizio Carta, Jean-Yves Winum, Paul C. McDonald
  • Publication number: 20140148505
    Abstract: The present invention relates to methods and compositions for predicting drug responses. In particular, the present invention provides methods and compositions for determining individualized Warfarin dosages based on genotype of DNA polymorphisms and haplotypes derived from them in the VKORC1 gene.
    Type: Application
    Filed: November 7, 2013
    Publication date: May 29, 2014
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Mark J. Rieder, Allan Rettie
  • Publication number: 20140135388
    Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 15, 2014
    Inventors: Gunther BERNDL, Joerg BREITENBACH, Robert HEGER, Joerg ROSENBERG, Michael STADLER, Peter WILKE
  • Publication number: 20140128362
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment (particularly for reducing the risk of venous thrombosis). For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: March 20, 2013
    Publication date: May 8, 2014
    Applicant: CELERA CORPORATION
    Inventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
  • Patent number: 8716233
    Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 6, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
  • Publication number: 20140105920
    Abstract: Described herein are compositions and methods for preventing and/or treating diseases involving aberrant angiogenesis employing one or more benzo[c]chromen-6-one derivatives.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 17, 2014
    Inventor: David Sherris
  • Patent number: 8673983
    Abstract: The present invention provides an enzymatic and a chemical synthesis of melanins and novel melanins.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: March 18, 2014
    Assignee: Loyola University Chicago
    Inventors: Earle W. Holmes, Kenneth D. Thompson
  • Publication number: 20140050676
    Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 20, 2014
    Applicant: Conopco, Inc., d/b/a UNILEVER
    Inventor: Conopco, Inc., d/b/a UNILEVER
  • Patent number: 8653129
    Abstract: The present invention provides a novel therapeutic combination comprising one or more anti-androgen agents and one or more antibiotic/anti-inflammatory agents or pharmaceutically acceptable salts or hydrates thereof, useful for the treatment of a dermatological disorder.
    Type: Grant
    Filed: April 11, 2011
    Date of Patent: February 18, 2014
    Assignee: M. Alphabet 1, LLC
    Inventors: Howard Fein, Mindy B. Berlin
  • Publication number: 20140037708
    Abstract: The present invention provides a biocompatible composition that comprises a bioactive material and a method for using the same. In particular, the composition of the invention is useful for spatio and/or temporal release of the bioactive material. Specifically, the composition of the invention comprises at least one polymeric mixture layer comprising a plurality of biodegradable polymers. The polymeric mixture layer comprises a first biodegradable polymer and a second biodegradable polymer. The relative amount of the first biodegradable polymer or the second biodegradable polymer increases within the polymeric mixture layer in one direction, and the relative amount of the other biodegradable polymer decreases in the polymeric mixture layer in the same direction. The rate of degradation of the first biodegradable polymer is different from the rate of degradation of the second biodegradable polymer. In this manner, the composition allows spatio and/or temporal release of the bioactive material.
    Type: Application
    Filed: July 30, 2013
    Publication date: February 6, 2014
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Wei Tan, Walter Bonani
  • Publication number: 20130309290
    Abstract: A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal stent, and more specific beneficial applications is an endovascular stent, and the gamma-tocopherol elutes from a coating or carrier coupled with the stent. Certain combinations are provided with the des-methyl-tocopherol or phytyl substituted chromanol, e.g. gamma-tocopherol, combined with an additional agent such as an anti-restenosis agent, e.g. sirolimus, tacrolimus, everolimus, or paclitaxel, in order to provide synergistic benefit to tissues along the stented or recanalized regions. Other forms of tocopherol or tocotrienol, or other phytyl substituted chromanols, and other compounds such as palm oil, are ailso contemplated. for use to treat restenosis.
    Type: Application
    Filed: July 29, 2013
    Publication date: November 21, 2013
    Applicant: CeloNova BioSciences, Inc.
    Inventors: James W. Larrick, James C. Peacock, III